Literature DB >> 21310281

Levonorgestrel-releasing and copper intrauterine devices and the risk of breast cancer.

Jürgen Dinger1, Kristina Bardenheuer, Thai Do Minh.   

Abstract

BACKGROUND: This study compares the risk of breast cancer for levonorgestrel-releasing intrauterine devices (LNG(IUD)) versus copper IUDs (CU(IUD)) in women younger than 50 years of age. STUDY
DESIGN: Retrospective, population-based, case-control study using cancer registers in Finland and Germany, powered to exclude a 1.5-fold risk of breast cancer.
RESULTS: Analysis of 5113 breast cancer cases diagnosed 2000-2007 and 20,452 controls - matched by year of birth and area of residence - yielded relative risk estimates approaching unity with 95% CI crossing 1.0 for all comparisons, including ever-use of LNG(IUD) versus CU(IUD) (adjusted OR, 0.99; 95% CI, 0.88-1.12) and current use at time of diagnosis (adjusted OR, 0.85; 95% CI, 0.52-1.39), as well as for sub-analyses by country, age, tumor characteristics and period, recency and duration of use prior to diagnosis.
CONCLUSION: This study does not indicate an increased risk of breast cancer for users of LNG(IUD). No indications for tumor promotion or tumor induction were found.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21310281     DOI: 10.1016/j.contraception.2010.11.009

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  16 in total

Review 1.  Contraception in women over 40 years of age.

Authors:  Rebecca H Allen; Carrie A Cwiak; Andrew M Kaunitz
Journal:  CMAJ       Date:  2013-03-04       Impact factor: 8.262

2.  Hormonal contraception and breast cancer.

Authors:  Carolyn L Westhoff; Malcolm C Pike
Journal:  Contraception       Date:  2018-09       Impact factor: 3.375

3.  Loss of progesterone receptor through epigenetic regulation is associated with poor prognosis in solid tumors.

Authors:  Yiyang Li; Cheng Huang; Tamar Kavlashvili; Abby Fronk; Yuping Zhang; Yang Wei; Donghai Dai; Eric J Devor; Xiangbing Meng; Kristina W Thiel; Kimberly K Leslie; Shujie Yang
Journal:  Am J Cancer Res       Date:  2020-06-01       Impact factor: 6.166

Review 4.  Reproductive health care across the lifecourse of the female cancer patient.

Authors:  Lisa A Rubinsak; Mindy S Christianson; Aletha Akers; Jeanne Carter; Andrew M Kaunitz; Sarah M Temkin
Journal:  Support Care Cancer       Date:  2018-07-26       Impact factor: 3.603

Review 5.  Exogenous reproductive hormone use in breast cancer survivors and previvors.

Authors:  Ines Vaz-Luis; Ann H Partridge
Journal:  Nat Rev Clin Oncol       Date:  2018-01-23       Impact factor: 66.675

Review 6.  Breast cancer under age 40: a different approach.

Authors:  D Ribnikar; J M Ribeiro; D Pinto; B Sousa; A C Pinto; E Gomes; E C Moser; M J Cardoso; F Cardoso
Journal:  Curr Treat Options Oncol       Date:  2015-04

7.  Contraception for Adolescents During the Coronavirus Disease 2019 Pandemic.

Authors:  Tracey A Wilkinson; Melissa J Kottke; Elise D Berlan
Journal:  JAMA Pediatr       Date:  2021-03-01       Impact factor: 16.193

Review 8.  Influence of the levonorgestrel-releasing intrauterine system on the risk of breast cancer: a systematic review.

Authors:  Aline Zürcher; Laura Knabben; Heidrun Janka; Petra Stute
Journal:  Arch Gynecol Obstet       Date:  2022-06-18       Impact factor: 2.344

9.  Hormonal contraception and breast cancer.

Authors:  Carolyn L Westhoff; Malcolm C Pike
Journal:  Am J Obstet Gynecol       Date:  2018-05-17       Impact factor: 8.661

Review 10.  Caring for the breast cancer survivor's health and well-being.

Authors:  Petra M Casey; Stephanie S Faubion; Kathy L MacLaughlin; Margaret E Long; Sandhya Pruthi
Journal:  World J Clin Oncol       Date:  2014-10-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.